Atossa Therapeutics Investor Relations Material
Latest events
Q2 2023
Atossa Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Atossa Therapeutics Inc
Access all reports
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company developing medicines that address significant unmet medical needs in oncology, with a specific focus on breast cancer. The company's lead program is Endoxifen, an active metabolite of tamoxifen, currently in clinical trials for the treatment and prevention of breast cancer. Additionally, Atossa is working on AT-H201 for lung injury caused by cancer treatment and is involved in developing immunotherapy/chimeric antigen receptor therapy programs. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Latest articles
The World of Luxury: Creating and Selling Desirability
Dive into the enchanting world of high-end allure, where the art of exclusivity shapes desire, turning luxury into an emblem of unique prestige.
6 May 2024
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
3 May 2024
Microsoft's Journey to Becoming the World's Most Valuable Company
Explore Microsoft's rise from a garage startup to the world's most valuable company, highlighting Bill Gates' role in shaping the digital revolution.
3 May 2024
Ticker symbol
Country
đșđž United States